Cardiorenal Collaboration: Optimizing Multidisciplinary Care in the CvRM Patient

Host: Raymond Townsend, MD

Guest: Melissa Magwire, RN, MSN, CDE

Guest: Michael Weber, MD


The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.